Company: IMRX
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001790340-25-000104
Chunk: 376

Company: Immuneering Corp
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 8
Chunk 376
---
 and 2024:Six Months Ended June 30,20252024Weighted-average risk-free interest rate4.01% - 4.55%3.93% - 4.82%Expected term (in years)5.51 - 10.005.00 - 10.00Expected dividend yield0%0%Expected volatility65.86% - 67.33%66.08% - 69.85%The following table summarizes the stock option activity during the six months ended June 30, 2025:Number of OptionsWeighted- Average Exercise Price per ShareWeighted Average Remaining Contractual Term (in Years)Aggregate Intrinsic ValueOutstanding at December 31, 20246,382,149$4.40 Granted2,317,2941.89 Exercised(1,604)1.28 Cancelled(292,467)2.96 Outstanding at June 30, 20258,405,372$3.78 7.66$5,098,323 Vested and exercisable at June 30, 20254,638,867$4.60 6.66$1,612,350 For the three and six months ended June 30, 2025 and 2024, the Company recognized share-based compensation expense on the accompanying condensed consolidated statements of operations as follows:Three Months Ended June 30,Six Months Ended June 30,2025202420252024Research and development$610,369 $678,377 $1,343,405 $1,245,261 General and administrative914,574 983,372 1,873,805 1,891,246 Total$1,524,943 $1,661,749 $3,217,210 $3,136,507 

Note 10 – Commitments and Contingencies

Operating LeasesAs part of the BioArkive acquisition, the Company assumed the obligations of three leases in San Diego, California. The first lease is for 38,613 square feet of office and laboratory space, under a lease that terminates on April 30, 2032; the second lease was for 6,100 square feet of office and laboratory space under a lease that terminated on December 31, 2022 (and that was not renewed); and the third lease was for 4,760 square feet of office and laboratory space under a lease that